Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T77664
(Former ID: TTDC00096)
|
||||
Target Name |
Interferon-gamma (IFNG)
|
||||
Synonyms |
Interferon gamma; Immune interferon; IFN-gamma
|
||||
Gene Name |
IFNG
|
||||
Target Type |
Successful target
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | Adaptive immunity immunodeficiency [ICD-11: 4A01] | ||||
Function |
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
|
||||
BioChemical Class |
Cytokine: interferon
|
||||
UniProt ID | |||||
Sequence |
MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWK
EESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTN YSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ |
||||
Drugs and Modes of Action | |||||
Approved Drug(s) | [+] 1 Approved Drugs | + | |||
1 | Emapalumab | Drug Info | Approved | Primary haemophagocytic lymphohistiocytosis | [1] |
Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | |||
1 | Fumaric acid | Drug Info | Phase 3 | Multiple sclerosis | [2] |
2 | VIR-201 | Drug Info | Phase 1/2 | Human immunodeficiency virus infection | [3] |
3 | AMG 811 | Drug Info | Phase 1 | Systemic lupus erythematosus | [4] |
4 | CIGB-128 | Drug Info | Phase 1 | Basal cell carcinoma | [5] |
Discontinued Drug(s) | [+] 4 Discontinued Drugs | + | |||
1 | CRx-191 | Drug Info | Discontinued in Phase 2 | Psoriatic disorder | [6] |
2 | Fontolizumab | Drug Info | Discontinued in Phase 2 | Rheumatoid arthritis | [7] |
3 | TAK-603 | Drug Info | Discontinued in Phase 2 | Inflammatory bowel disease | [8] |
4 | TG-1042 | Drug Info | Discontinued in Phase 2 | B-cell lymphoma | [9] |
Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | |||
1 | VPM-4-001 | Drug Info | Preclinical | Prostate cancer | [10] |
Mode of Action | [+] 3 Modes of Action | + | |||
Modulator | [+] 6 Modulator drugs | + | |||
1 | Emapalumab | Drug Info | [1] | ||
2 | VIR-201 | Drug Info | [11] | ||
3 | AMG 811 | Drug Info | [12] | ||
4 | CIGB-128 | Drug Info | [13] | ||
5 | TAK-603 | Drug Info | [16] | ||
6 | TG-1042 | Drug Info | [17] | ||
Binder | [+] 1 Binder drugs | + | |||
1 | Fumaric acid | Drug Info | [2] | ||
Inhibitor | [+] 1 Inhibitor drugs | + | |||
1 | CRx-191 | Drug Info | [14] | ||
Target Regulators | |||||
Target-regulating microRNAs | |||||
Target-regulating Transcription Factors | |||||
Target-interacting Proteins | |||||
Target Profiles in Patients | |||||
Target Expression Profile (TEP) | |||||
Target Affiliated Biological Pathways | |||||
KEGG Pathway | [+] 28 KEGG Pathways | + | |||
1 | Proteasome | ||||
2 | Cytokine-cytokine receptor interaction | ||||
3 | HIF-1 signaling pathway | ||||
4 | Regulation of autophagy | ||||
5 | TGF-beta signaling pathway | ||||
6 | Osteoclast differentiation | ||||
7 | Antigen processing and presentation | ||||
8 | Jak-STAT signaling pathway | ||||
9 | Natural killer cell mediated cytotoxicity | ||||
10 | T cell receptor signaling pathway | ||||
11 | Type I diabetes mellitus | ||||
12 | Salmonella infection | ||||
13 | Leishmaniasis | ||||
14 | Chagas disease (American trypanosomiasis) | ||||
15 | African trypanosomiasis | ||||
16 | Malaria | ||||
17 | Toxoplasmosis | ||||
18 | Amoebiasis | ||||
19 | Tuberculosis | ||||
20 | Measles | ||||
21 | Influenza A | ||||
22 | Herpes simplex infection | ||||
23 | Epstein-Barr virus infection | ||||
24 | Inflammatory bowel disease (IBD) | ||||
25 | Systemic lupus erythematosus | ||||
26 | Rheumatoid arthritis | ||||
27 | Allograft rejection | ||||
28 | Graft-versus-host disease | ||||
NetPath Pathway | [+] 4 NetPath Pathways | + | |||
1 | IL1 Signaling Pathway | ||||
2 | TCR Signaling Pathway | ||||
3 | IL2 Signaling Pathway | ||||
4 | Leptin Signaling Pathway | ||||
Panther Pathway | [+] 2 Panther Pathways | + | |||
1 | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
2 | Interferon-gamma signaling pathway | ||||
PID Pathway | [+] 16 PID Pathways | + | |||
1 | IL27-mediated signaling events | ||||
2 | IL12-mediated signaling events | ||||
3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
4 | SHP2 signaling | ||||
5 | Regulation of Telomerase | ||||
6 | Glucocorticoid receptor regulatory network | ||||
7 | IL2-mediated signaling events | ||||
8 | IFN-gamma pathway | ||||
9 | ATF-2 transcription factor network | ||||
10 | AP-1 transcription factor network | ||||
11 | IL23-mediated signaling events | ||||
12 | PDGFR-alpha signaling pathway | ||||
13 | Calcium signaling in the CD4+ TCR pathway | ||||
14 | Downstream signaling in naï | ||||
15 | |||||
16 | IL12 signaling mediated by STAT4 | ||||
Reactome | [+] 2 Reactome Pathways | + | |||
1 | Interferon gamma signaling | ||||
2 | Regulation of IFNG signaling | ||||
WikiPathways | [+] 16 WikiPathways | + | |||
1 | Type II interferon signaling (IFNG) | ||||
2 | Senescence and Autophagy in Cancer | ||||
3 | TGF Beta Signaling Pathway | ||||
4 | Cytokines and Inflammatory Response | ||||
5 | Hypertrophy Model | ||||
6 | Inflammatory Response Pathway | ||||
7 | Aryl Hydrocarbon Receptor Pathway | ||||
8 | IL1 and megakaryotyces in obesity | ||||
9 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
10 | Spinal Cord Injury | ||||
11 | Allograft Rejection | ||||
12 | Interferon gamma signaling | ||||
13 | Proteasome Degradation | ||||
14 | Folate Metabolism | ||||
15 | Vitamin B12 Metabolism | ||||
16 | Selenium Micronutrient Network | ||||
Target-Related Models and Studies | |||||
Target Validation | |||||
References | |||||
REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | ||||
REF 2 | Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. | ||||
REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010310) | ||||
REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028077) | ||||
REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037683) | ||||
REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025635) | ||||
REF 7 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | ||||
REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006011) | ||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010265) | ||||
REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023655) | ||||
REF 11 | EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents. | ||||
REF 12 | Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53. | ||||
REF 13 | Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. | ||||
REF 14 | CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008. | ||||
REF 15 | Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. | ||||
REF 16 | T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11. | ||||
REF 17 | Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8. | ||||
REF 18 | BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.